Key facts
- This page summarizes Reginald J. Sanders's Form 4 filing for EyePoint Pharmaceuticals, Inc. (EYPT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 08 Jan 2025, 16:14.
Reginald J. Sanders - 08 Jan 2025 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)
- Reporting relationship
- Director
- Issuer ticker
- EYPT
- Reported as of
- 08 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Jan 2025, 16:14:00 UTC
- Next SEC filing
- 06 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ron Honig, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Reginald J. Sanders filed Form 4 for EyePoint Pharmaceuticals, Inc. (EYPT) on 08 Jan 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EYPT
transaction
Derivative
Stock Options (Right to buy)
Award
- Transaction value
- $0
- Shares
- +80,000
- Change %
- Price
- $0.000000
- Shares after
- 80,000
- Date
- 08 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 80,000
- Exercise price
- $9.11
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option becomes exercisable in three ratable annual installments beginning on January 8, 2026.